Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lonza GroupSGX:O6Z 82 OCF Margin % is 19.47% as of Jun. 2026, which is 3% below its 10-year median of 20.09. GuruFocus rates SGX:O6Z with a GF Score™ of 82/100 and a GF Value™ of S$82.87. The stock has 4 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Lonza Group ranks better than 79.31% on this metric.
The historical rank and industry rank for Lonza Group's OCF Margin % or its related term are showing as below:
SGX:O6Z'
s OCF Margin % Range Over the Past 10 Years
Min: 16.39 Med: 20.09 Max: 25.07
Current: 20.89
During the past 13 years, the highest OCF Margin % of Lonza Group was 25.07%. The lowest was 16.39%. And the median was 20.09%.
SGX:O6Z's OCF Margin % is ranked better than 79.31% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: 4.84
vs SGX:O6Z: 20.89
Lonza Group OCF Margin % Related Terms
Lonza Group OCF Margin % Historical Data
* Premium members only.
The historical data trend for Lonza Group's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SGX:O6Z vs TMO, DHR, IDXX: OCF Margin % Comparison
For the Diagnostics & Research subindustry, Lonza Group's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lonza Group OCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Lonza Group's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Lonza Group's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lonza Group (SGX:O6Z) has a OCF Margin % of 19.47% as of Jun. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Lonza Group and its competitors. This is near median its historical median of 20.09. Over the past decade, Lonza Group's OCF Margin % has ranged from 16.39 to 25.07. According to the industry distribution chart, Lonza Group ranks #42 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 20.7%.
Is Lonza Group's OCF Margin % too high?
Lonza Group's current OCF Margin % of 19.47% is near median its 10-year median of 20.09. Over the past 10 years, this metric has ranged from a low of 16.39 to a high of 25.07. The Medical Diagnostics & Research industry median OCF Margin % is 4.84. Lonza Group's value of 19.47% is 302.3% above this industry median. Based on the distribution chart, Lonza Group ranks #42 out of 203 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Lonza Group has a GF Score™ of 82/100, reflecting its overall financial health beyond just this single metric.
How does Lonza Group's OCF Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Lonza Group ranks #42 out of 203 companies for OCF Margin %. This places Lonza Group in the top 21% of its industry — outperforming the majority of peers. The industry median OCF Margin % is 4.84. Lonza Group's value of 19.47% is 302.3% above this benchmark. Historically, Lonza Group's own OCF Margin % has ranged from 16.39 to 25.07 over the past decade. While the company's 10-year median is 20.09 vs. the industry median of 4.84, Lonza Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Diagnostics & Research company?
The median OCF Margin % among Medical Diagnostics & Research companies is 4.84, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lonza Group's current OCF Margin % of 19.47% is 302.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Lonza Group and its competitors. For the Medical Diagnostics & Research industry, the median OCF Margin % is 4.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lonza Group's current OCF Margin % is 19.47%, which is near median its own 10-year median of 20.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lonza Group stock overvalued right now?
Lonza Group (SGX:O6Z) has a current OCF Margin % of 19.47%. The stock's GF Value™ is S$82.87, compared to a current price of S$79.97 — trading 3.5% below its estimated fair value. The current OCF Margin % is 19.47%, which is near median its 10-year median of 20.09 and 302.3% above the Medical Diagnostics & Research industry median of 4.84. Lonza Group's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Lonza Group (SGX:O6Z), the current OCF Margin % is 19.47% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lonza Group (SGX:O6Z) Overvalued in 2026?
Based on GuruFocus' analysis, Lonza Group stock appears to be undervalued.
The current stock price of S$79.97 is trading 3.5% below its estimated GF Value™ of S$82.87.
Key valuation signals for SGX:O6Z:
OCF Margin %: 19.47% (near median its 10-year median of 20.09)
GF Value™: S$82.87 vs. price of S$79.97 (3.5% below fair value)
Industry Position: 302.3% above the Medical Diagnostics & Research median (#42 of 203)
No single metric tells the full story. See the SGX:O6Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lonza Group is a contract development and manufacturing organization. It operates under four segments: small molecules, biologics, cell and gene, and capsules and health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides development and manufacturing services throughout the entire lifecycle of a product, from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations.
82GF Score
Get the complete analysis for SGX:O6Z
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGX:O6Z has been successfully added to your 
